Dual-drug sustained-release carrier: Preparation and performance

doi:10.3969/j.issn.2095-4344.2013.29.013

Abstract

Abstract:

BACKGROUND: During conventional treatment for bone tuberculosis, there is a low effective concentration of anti-tuberculosis drugs, and the therapeutic effect is poor.
OBJECTIVE: To develop a new biomaterial as a slow-release artificial carrier that can be directly implanted into the surrounding tissue of bone tuberculosis, maintain a certain anti-tuberculosis drug concentration for a long time, thereby playing an effective therapeutic action.
METHODS: Rifampicin/polylactic acid/glycolic acid microspheres and isoniazid/polylactic acid/glycolic acid microspheres were prepared using the emulsion-solvent evaporation method. Using α-cyanoacrylate, a biological adhesive, two kinds of microspheres were processed into a long-term slow-release bicomponent drug carrier. Then, in vitro release characteristics of the dual-drug sustained-release carrier were observed. After that, the dual-drug sustained-release carrier was implanted into rabbit intertrochanteric femur bone defects for observing drug release concentrations, histocompatibility and bone defect healing at different time points after drug delivery carrier implantation.
RESULTS AND CONCLUSION: For rifampicin/polylactic acid/glycolic acid microspheres, the mean particle size was (240±13) μm, and the drug loading load rate was (26±1.5)%. For isoniazid/polylactic acid/glycolic acid microspheres, the mean particle size was (250±10) μm, and drug loading rate was (28±1.8)%. The in vitro cumulative release rate could reach 80% for rifampicin and 90% for isoniazid at day 90. The in vivo released concentration of rifampicin and isoniazid within 90 days was (0.5±0.4) and (0.6±0.3) μg/g, respectively. There were a small amount of infiltrated neutrophils between the fascia and muscle fibers after the drug delivery carrier was implanted, and the amount of neutrophils in the muscle were reduced significantly at day 59. X-ray plain film showed that bone defects decreased obviously in size. These findings indicate that this dual-drug sustained-release carrier can maintain a certain anti-tuberculosis drug concentration in the surrounding tissues of bone tuberculosis, which is expected to provide a new type of dual-drug delivery carrier in the surgical treatment of bone tuberculosis.

Key words: biomaterials, biomaterials and controlled drug release, isoniazid, rifampicin, polylactic acid-glycolic acid copolymer, slow release, in vitro, in vivo, bone tuberculosis, provincial grants-supported paper

CLC Number:

R318

Bao Yu-cheng, Zhang Wen-long, Wang Yong, Zhang Jie, Wang Yong-mei. Dual-drug sustained-release carrier: Preparation and performance[J]. Chinese Journal of Tissue Engineering Research, 2013, 17(29): 5345-5350.

Figures/Tables 5

References

[1] Sundararaj GD, Behera S, Ravi V, et al. Role of posterior stabilisation in the management of tuberculosis of the dorsal and lumbar spine. J Bone Joint Surg Br. 2003;85(1):100-106.

[2] 施建党,王自立,马小民.病灶清除植骨内固定治疗相邻多椎体脊柱结核[J].中国脊柱脊髓杂志,2010,20(2):98-102.

[3] Ozdemir HM, Us AK, O?ün T. The role of anterior spinal instrumentation and allograft fibula for the treatment of pott disease. Spine (Phila Pa 1976). 2003;28(5):474-479.

[4] 瞿东滨,金大地.正确认识脊柱结核病灶清除术[J].中国脊柱脊髓杂志,2008,18(8):565-567.

[5] 第四届全国脊柱及骨关节结核病专题研讨会纪要[J].中国脊柱脊髓杂志,2010,20(11):965-968.

[6] Kumar G, Sharma S, Shafiq N, et al. Pharmacokinetics and tissue distribution studies of orally administered nanoparticles encapsulated ethionamide used as potential drug delivery system in management of multi-drug resistant tuberculosis. Drug Deliv. 2011;18(1):65-73.

[7] 郭虹,李环,李淑芬,等.抗结核药所致肝损害的发生机制及影响因素[J].北华大学学报(自然科学版),2006,7(2):159-161.

[8] 毕经瑞,苏华田,程莹,等.抗结核药物致肝损127例分析[J].中国防痨杂志,2002,24(4):233-235.

[9] 刘会民,张洁,张永进.我院异烟肼血药浓度监测结果分析[J].天津药学2011,23(6):27-28.

[10] 田洪英,王洪星,姚明.抗结核药血药浓度监测及临床疗效与安全性分析[J].中国药房,2012,23(26):2485-2487.

[11] 王自立.脊柱结核的病灶清除与融合固定问题[J].中国脊柱脊髓杂志,2006,16(12):888-889.

[12] Ge Z, Wang Z, Wei M. Measurement of the concentration of three antituberculosis drugs in the focus of spinal tuberculosis. Eur Spine J. 2008;17(11):1482-1487.

[13] 鲍玉成,张文龙,王勇,等.长效缓释双药物人工骨的制备及释放特性[J].中国组织工程研究,2012,16(38):7126-7130.

[14] 刘江涛,王永清,夏侃,等.异烟肼聚乳酸缓释体的制备及体内外释药特性[J].中国脊柱脊髓杂志,2008,18(4):290-293.

[15] Arshady R. Microspheres and microcapsules, a survey of manufacturing techniques: Part III: Solvent evaporation. Polym Eng Sci. 1990;30(15):915-924.

[16] 叶向阳,孙湘,贾会文,等.利福平聚乳酸-聚羟基乙酸缓释微球的制备及特性[J].中国组织工程研究与临床康复,2011;15(51): 9608-9612.

[17] 叶向阳,甄平,李晓飞,等.新型抗结核多孔磷酸钙骨水泥缓释载体的制备与性能研究[J].中国矫形外科杂志2010,18(23):1981-1986.

[18] 应小樟,徐华梓,彭磊,等.利福平硫酸钙植入剂的研制与相关性能检测[J].温州医学院学报,2007,1(37):50-55.

[19] 罗培培,左奕,孙斌,等.载异烟肼聚己内酯微球的制备及其性质研究[J].功能材料,2011,42(8):1410-1414.

[20] Loo SC, Tan ZY, Chow YJ, et al. Drug release from irradiated PLGA and PLLA multi-layered films. J Pharm Sci. 2010;99(7): 3060-3071.

[21] Parveen S, Sahoo SK. Polymeric nanoparticles for cancer therapy. J Drug Target. 2008;16(2):108-123.

[22] 张宏其,高琪乐,郭虎兵,等.人同种异体骨载异烟肼-壳聚糖缓释微球的制备和体内外释药特性[J].中国组织工程研究,2012, 16(3):479-483.

[23] World Health Organization. Global tuberculosis report 2012 [EB/OL]. http://www.who.int/tb/publications/global_report/en/

[24] 戈朝晖,王自立,魏敏吉.脊柱结核病灶中抗痨药物浓度的测定[J].中华骨科杂志,2005,25(2):97-101.

[25] Pawar UM, Kundnani V, Agashe V, et al. Multidrug-resistant tuberculosis of the spine--is it the beginning of the end? A study of twenty-five culture proven multidrug-resistant tuberculosis spine patients. Spine (Phila Pa 1976). 2009;34(22):E806-810.

[26] 肖文德,姬广林,高辉.脊柱结核的诊断与外科治疗进展[J].中国矫形外科杂志,2008,16(5):359-361.

[27] 施建党,王自立.脊柱结核术后未愈及术后复发的原因探讨[J].中国矫形外科杂志,2005,13(15):1184-1186.

[28] 付裕,霍洪军,肖宇龙,等.强化抗结核药物联合手术治疗胸腰椎结核[J].中国修复重建外科杂志,2009,23(12):1427-1430.

[29] 杨君礼,袁牧,许刚,等.利福平粉剂在脊柱结核病灶清除术中的应用观察[J].颈腰痛杂志,2005,26(4):270-273.

[30] Dutt M, Khuller GK. Chemotherapy of Mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in Poly (DL-lactide-co-glycolide) microparticles. J Antimicrob Chemother. 2001;47(6):829-835.

[31] 张厚安,李敏,唐思文.骨组织工程用细胞支架生物材料的研究进展[J].机械工程材料,2007,31(12):4-7.

[32] 龚明明,谭丽丽,杨柯.骨组织工程支架材料及其力学性能[J].材料导报,2007,21(10):43-46.